Moderna Inc. (MRNA) shares soared 15% Tuesday as the vac🦩cine maker got two pieces of positive news.

First, 澳洲幸运5官方开奖结果体彩网:Chief Executive Officer (CEO) Stephane Bancel said he believes the company would experience sales growth in 2025. In a letter to shareholders Tuesday, Bancel said the company is optimistic as it expects the launch of Moderna’s respiratory syncytial virus (RSV) vaccine candidate this year and could potentially launch of a combination flu/COVID-19 shot as early as 2025.

Along with Bancel’s comments, Moderna shares got a lift Tuesday when brokerage firm Oppenheimer & Co. upgraded the stock to "澳洲幸运5官方开奖结果体彩网:outperform," arguing that Moderna could develop ways to use its 澳洲幸运5官方开奖结果体彩网:mRNA technique to fight diseases beyond COVID-19 over the next few years.

Analysts at Oppenheimer led by Hartaj Singh wrote they believe the company will have✤ five new products on the market by 2026.

Currently, Moderna's COVID-19 vaccines are its only commercially available products. Over the next two years, the company sa🔴id it will focus on increasing revenue and profitability in part by targeting commercial execution.

Sales struggled as fewer people opted to get COVID-19 vaccinations or booster shots in 2023. That sent shares tumbling more than 40% last year, making it one of the stocks in the S&P 500 that 澳洲幸运5官方开奖结果体彩网:struggled the most.